Compare Oscar Health Inc (OSCR) vs Workday Inc (WDAY) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

Workday (WDAY) trades at $141.17, down 2.49% amid a Morgan Stanley downgrade (July 21, 2026). The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, WDAY maintains strong revenue growth ($8.45B in 2025) and consistent earnings beats, with Q1 2026 EPS of $2.66 exceeding expectations. The company's agentic AI initiatives are driving expansion deals, highlighted by a 200% YoY growth in new contract value.

WDAY presents a compelling growth opportunity with a consensus price target of $150.83 (6.8% upside), supported by 55.55% analyst buy ratings. However, risks include AI competition, regulatory scrutiny over HR software bias (Reuters, June 22, 2026), and elevated valuation multiples (P/E of 45.86). Investors should weigh robust fundamentals against near-term sentiment headwinds from the recent downgrade.